Brenus Pharma Secures €22.2M ($25M) to Accelerate Cancer Vaccine Trials

Sep 18, 2024, 07:37 AM

Brenus Pharma, a Lyon-based biotech company specializing in the development of precision cancer vaccines, has successfully raised €22.2 million ($25 million) in a Series A funding round. The financing was led by Angelor and will be used to accelerate clinical trials of its cancer vaccines. This significant investment underscores the growing interest and support for innovative cancer treatment solutions in the biotech sector.